There’s more bad news for β-secretase 1 (BACE1) inhibitors, a class of Alzheimer disease (AD) drug designed to reduce amyloid plaques by controlling amyloid processing upstream of anti-amyloid antibodies and of γ-secretase inhibitors. Just weeks after Merck & Co. published the results of its failed pivotal trial of verubecestat in mild-to-moderate AD, Johnson & Johnson and partner Shionogi have terminated late-stage development of atabecestat in asymptomatic individuals owing to safety concerns… Para acessar a publicação na íntegra clique aqui Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME…
Indian biotech sector readies for liftoff
The Indian government has unveiled bold plans to rekindle its homegrown biotech industry, allocating Rs. 24 billion ($372 million) for 2018–2019, the Department of Biotechnology (DBT) announced on February 1. The new spending will support 300 to 500 startups a year—aiming to reach 2,000 by 2020—two bioclusters, 15 bioincubators and three regional entrepreneurship centers. The earmarked funds will also help support 150 technology transfer offices and 20 ‘Bioconnect’ offices dedicated to providing access to incubators, mentors, investors, know-how and connections with the international market… Para acessar a publicação na íntegra clique aqui Fonte: 380 VOLUME…
Drug pipeline: 1Q18
Approvals were down last quarter. Vertex (Cambridge, MA, USA) got a green light for its small-molecule combination to combat cystic fibrosis; Theratechnologies (Montreal, Quebec, Canada) and Sun Pharmaceuticals (Mumbai, India) received registrations for monoclonal antibodies (mAbs) to treat HIV and psoriasis, respectively… Para acessar a publicação na íntegra clique aqui Fonte: 386 VOLUME 36 NUMBER 5 MAY 2018 NATURE BIOTECHNOLOGY…
FDA new drug approvals in Q1 2018
The first quarter of the year saw two notable FDA approvals for HIV therapies. In early February, Gilead Sciences gained approval for its triple combination product Biktarvy, which brings together the novel HIV-1 integrase inhibitor bictegravir with the established dual nucleoside reverse transcriptase inhibitor (NRTI) backbone of emtricitabine and tenofovir alafenamide in a once-daily, oral tablet formulation. Biktarvy is set to be one of 2018’s biggest launches and Gilead’s largest growth driver, with forecast sales of more than US$5 billion in 2022… Para acessar a publicação na íntegra clique aqui Fonte: NATURE REVIEWS…